DATA GRAPHICS | Data Byte
Efficacy of Pfizer COVID pill hits swath of COVID vax, mAb stocks
Selection of COVID vaccine, mAb players collectively lose $62.5B on Pfizer data
November 6, 2021 1:44 AM UTC
Investors are revising their expectations about how much, and for how long, COVID-19 vaccines and mAb therapies may be needed after Pfizer disclosed strong efficacy data Friday for its oral protease inhibitor.
COVID-19 vaccine, mAb, and therapeutics companies were all susceptible, and several got hammered on Friday...